Does hydroxychloroquine cause retinal toxicity?

Does Hydroxychloroquine Cause Visual Toxicity?

Yes, hydroxychloroquine definitively causes retinal toxicity, which can lead to irreversible vision loss, but the risk is dose-dependent and duration-dependent, remaining below 2% in the first 10 years when dosed at ≤5.0 mg/kg actual body weight. 1, 2, 3

Understanding the Risk

The overall prevalence of hydroxychloroquine retinopathy is 7.5% among patients using the drug for more than 5 years, but this varies dramatically based on dosing and duration 2. The risk escalates sharply to approximately 20% after 20 years of use 2. This is substantially higher than previously recognized because modern screening techniques (OCT and visual fields) detect toxicity before the classic "bull's-eye" maculopathy becomes visible on fundus examination 2.

Critical Risk Factors

Primary determinants:

• Daily dose >5.0 mg/kg actual body weight is the single most critical risk factor (odds ratio 5.67) 4
• Duration of use >10 years significantly increases risk (odds ratio 3.22) 4
• Patients staying at ≤5.0 mg/kg have <1% risk in first 5 years and <2% up to 10 years 2

Additional major risk factors:

• Renal disease (CKD stage 3 or greater): HR 1.95-2.08 5, 4
• Tamoxifen use: HR 3.43-4.59 5, 4
• Older age at initiation: HR increases from 2.48 (age 45-54) to 5.68 (age ≥65) compared to <45 years 5
• Female sex: HR 3.83 5

Nature of the Toxicity

The retinopathy is irreversible and can progress even after stopping the drug 2. The damage primarily affects photoreceptors, with secondary RPE disruption 2. Most patients remain asymptomatic until advanced stages, making screening essential 2.

Pattern Variations by Ethnicity

• European descent: Parafoveal (classic) pattern 2
• Asian descent: Pericentral/extramacular pattern near the arcades 2
• African-Americans and Hispanics: Predominantly parafoveal but with greater tendency toward extramacular involvement 2

This ethnic variation is critical because it affects screening strategy—Asian patients require wider visual field testing (24-2 or 30-2 patterns instead of 10-2) 2.

Screening Protocol

Baseline examination (within first year of starting HCQ) 2:

• Fundus examination
• Automated visual fields (10-2 for non-Asian; 24-2 or 30-2 for Asian patients)
• Spectral-domain OCT
• Purpose: Rule out pre-existing macular disease and establish baseline

Annual screening 2:

• Begin after 5 years of use if no major risk factors
• Begin sooner if high-risk factors present (renal disease, tamoxifen use, dose >5.0 mg/kg, older age)
• Use both automated visual fields AND SD-OCT as primary tools
• Verify suspicious findings with repeat testing or additional modalities before diagnosing toxicity

Safe Dosing Recommendations

Keep daily dose ≤5.0 mg/kg of actual body weight 1, 2. This is a critical change from older recommendations that used ideal body weight—very thin patients are at increased risk when dose is calculated by ideal weight 2. The FDA label confirms irreversible retinal damage as a known risk and emphasizes dose-related toxicity 3.

Common Pitfall

Do not calculate dose based on ideal body weight. Use actual body weight to minimize risk, particularly in thin patients 2.

Clinical Management

If toxicity is detected:

• Discontinue hydroxychloroquine immediately 3
• Monitor closely—retinal changes may progress even after cessation 2
• Early-detected toxicity (before RPE damage) shows only mild, limited progression after stopping 2
• Late-detected toxicity (bull's-eye stage) can progress for years with foveal thinning and visual acuity loss 2

Important Caveats

While hydroxychloroquine carries definite ocular toxicity risk, it remains a valuable drug with fewer systemic side effects than many alternatives for autoimmune diseases 2. Screening should be viewed as enabling safe continuation of the drug (by not stopping for uncertain findings) as much as preventing serious damage (by early recognition of definitive findings) 2.

The drug should not be stopped for uncertain or equivocal findings—verify with multiple tests or repeat testing 1, 2. Effective communication among prescribing physicians, patients, and eye care providers is essential to optimize both utility and safety 1.